5/12/2010 9:56:12 AM
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Meda has acquired exclusive European rights to a new formulation of imiquimod from Graceway Pharmaceuticals. The new formulation is 3,75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). This product has recently been approved in the US and Canada.
comments powered by